

Index

- A**
- AAGAB, 38
- AAV. *See* Adeno-associated virus
- ABCA12, 47, 79–80, 436
- ABCC1, 347
- ABCC11, 118
- ABCG2, 347
- Acne vulgaris, microbiome, 249
- Acomys, 188
- ACTL6a, 293
- AD. *See* Alzheimer's disease; Atopic dermatitis
- Adeno-associated virus (AAV), gene therapy, 430
- Adenovirus (AdV), gene therapy, 430
- Adipocyte
- adipokines, 153
 - aging, 150–151
 - defects and disease, 153–156
 - development, 145, 147, 149
 - dynamics, 146–147
 - hair regeneration role, 149–150
 - hormone regulation, 151–152
 - metabolism, 152–153
 - precursors, 155–156
 - prospects for study, 156
 - wound healing, 147–148, 150
- Adiponectin, 153
- AdV. *See* Adenovirus
- Aging
- adipocytes, 150–151
 - overview, 257–258
 - skin effects
 - barrier function, 258–259
 - dermal structure
 - collagen fibril degradation, 261–264
 - extracellular matrix, 265–266
 - mechanical tension restoration of
 - extracellular matrix accumulation, 266 - overview, 261
 - fat, 261
 - immunity, 260
 - innervation, 260
 - pigmentary system, 259–260
 - regenerative capacity, 259
 - thermoregulation function, 258–259
 - vasculature, 260–261
- AKT, 99, 418–419
- ALDH3A2, 436
- Allergy, 207–208
- ALLO-1, 378
- ALLO-2, 378
- Alopecia
- alopecia areata
 - clinical presentation, 362–363
 - management, 363
 - pathogenesis, 363–364
- anagen effluvium
- clinical presentation, 364
 - management, 364–365
 - pathogenesis, 365
- androgenic alopecia
- clinical presentation, 360
 - management, 360
 - pathogenesis, 360, 362
- central centrifugal cicatricial alopecia
- clinical presentation, 368
 - management, 368–369
 - pathogenesis, 369
- chronic cutaneous lupus erythematosus
- clinical presentation, 366
 - management, 366
 - pathogenesis, 366–367
- lichen planopilaris
- clinical presentation, 367
 - management, 367–368
 - pathogenesis, 368
- loose anagen syndrome
- clinical presentation, 365
 - management, 364
 - pathogenesis, 365
- overview, 359–362
- prospects for study, 369–370
- telogen effluvium
- clinical presentation, 364
 - management, 364
 - pathogenesis, 364
- traction alopecia, 366
- trichotillomania
- clinical presentation, 365
 - management, 365
 - pathogenesis, 365–366
- ALOX12B, 80, 276
- ALOXE3, 80, 276
- Alzheimer's disease (AD), corneocyte gene mutations, 77

Index

- AMPK, 67
Anagen effluvium. *See* Alopecia
Anagen. *See* Hair follicle
ANCR, 275
Androgen receptor (AR), adipocytes, 152
Androgenic alopecia. *See* Alopecia
ANRIL, 276
Antigen-presenting cells (APCs), 194–195
Antimicrobial peptides
 barrier function, 83, 242
 fat layer immune function, 200
AP-1, 149, 172, 263, 319, 322
AP-3, 171
APCs. *See* Antigen-presenting cells
APECED syndrome, 209
Apocrine sweat gland. *See* Sweat gland
Apremilast, psoriasis management, 346
AR. *See* Androgen receptor
Arsenic trioxide (ATO), basal cell carcinoma management, 379
ARVC, 102, 104
Asymmetric cell division, 62–65
ATM, 309
ATO. *See* Arsenic trioxide
Atopic dermatitis (AD), microbiome, 247–249
ATP2A2, Darier's disease mutations, 36, 38
ATP2C1, Hailey–Hailey disease mutations, 35, 38
ATR, 309
Autoimmunity
 antibacterial-like autoimmunity, 209
 antibody-mediated autoimmunity, 219–211
 antiviral-like autoimmunity, 209–210
 malignancy, 211
 overview, 208–209
- B**
- BANCR, 276
BAP1, 413
Barrier function
 aging effects, 258–259
 assessment, 73–74
 components
 antimicrobial peptides, 82
 corneocytes and cornified envelope, 74, 76–78
 junctional proteins, 78–79
 lipids, 79–81
 proteases and inhibitors, 81–82
 transcription factors in development, 82–83
 desmosomes, 78–79, 99–100
 knockout mouse studies, 75–76
 prospects for study, 83–84
 tight junctions and cell polarity, 60–61
Basal cell carcinoma (BCC). *See also* Skin cancer
 Hedgehog mutations, 373–374
 treatment
 drug resistance, 377–378
 prospects, 378–381
 SMO inhibitors, 375–377
 traditional therapy, 374–375
Basal cell nevus syndrome (BCNS), 376
Basophil, dermal immune function, 198
B cell, dermal immune function, 199
BCC. *See* Basal cell carcinoma
BCNS. *See* Basal cell nevus syndrome
 β -Catenin
 dermal papilla, 217, 222
 desmosome protein interactions, 99
 hair follicle neogenesis, 190
BLIMP1, 9, 25
BLM, 174
BLOC-1, 175
BMPs. *See* Bone morphogenetic proteins
BMT. *See* Bone marrow transplantation
Bone marrow transplantation (BMT)
 epithelial progenitors, 460–461
 indications, 461
 recessive dystrophic epidermolysis, 459–460
 skin repair mechanism, 460
Bone morphogenetic proteins (BMPs)
 adipogenesis, 149–150
 hair follicle macroenvironment, 232, 236
 sweat gland development signaling, 121
BRAF, 276, 414–416, 418
Brg1, 292–293
Brm, 292–293
Bulge stem cell, markers, 5–8
- C**
- CARD14, 338, 347
Cardiovascular disease (CVD), psoriasis comorbidity, 333–334
Carney complex, 173
CCND1, 377, 421
CD200, bulge stem cell marker, 7
CD71, interfollicular stem cell expression, 9
CDK4, 412–413
CDKN2A, 411–413
CDSN. *See* Cornodesmosin
CE. *See* Cornified envelope
C/EBP
 adipogenesis, 149
 epidermal barrier formation role, 83
 epidermal differentiation role, 287
Cell polarity
 barrier formation role, 58, 60–61
 cell growth and metabolism studies, 66–67
 cilia formation, 61
 epidermal cell fate regulation, 62–64
 epidermal regeneration and migration role, 64–65
 immune signaling, 67

- overview, 58–60
 - prospects for study, 67–68
 - signaling networks, 59
 - skin cancer role, 65–66
 - Cell therapy. *See also* Induced pluripotent stem cell
 - bone marrow stem cells
 - mouse studies, 458
 - overview, 457–458
 - bone marrow transplantation
 - epithelial progenitors, 460–461
 - indications, 461
 - skin repair mechanism, 460
 - challenges in inherited skin disease, 444
 - epidermolysis bullosa
 - fibroblast cell therapy
 - overview, 444, 456
 - recessive dystrophic epidermolysis bullosa, 456–457
 - revertant cell therapy, 463
 - keratinocyte culture and skin grafting, 444
 - overview, 441–442, 445–455
 - prospects
 - bone marrow cell protocol refinement, 463–464
 - cell targeting to damaged skin, 464
 - gene therapy combination, 464
 - protein and drug therapy combination, 464–465
 - revertant mosaicism combination, 465
 - recessive dystrophic epidermolysis
 - bone marrow transplant, 459–460
 - mesenchymal stem cells, 458–459
 - revertant cell therapy, 463
 - umbilical cord blood, 461–462
 - Central centrifugal cicatricial alopecia. *See* Alopecia
 - Ceramide synthase, barrier function, 80
 - CGD. *See* Chronic granulomatous disease
 - CGHT. *See* Generalized hypertrichosis terminalis
 - Chediak–Higashi syndrome, 174
 - CHIPS, 203
 - Chromatin remodeling. *See* Epigenetics
 - Chronic cutaneous lupus erythematosus. *See* Alopecia
 - Chronic granulomatous disease (CGD), 198
 - Cilia, formation, 61
 - ClfA, 203
 - c-Myc, 475
 - COL7A1, 34, 37, 45, 170, 433–434, 444, 456–457, 479, 481
 - Collagen, fibril degradation in aging, 261–264
 - Complement
 - abnormalities, 200
 - fat layer immune function, 199
 - Cornified envelope (CE), barrier function, 74, 76–78
 - Cornodesmosin (CDSN), 99
 - COX. *See* Cyclooxygenase
 - CPT-1, 153
 - CR3, 205
 - Crb3, 61
 - CRISPR, 481
 - CSL, 314
 - CTLA4*, 45
 - CVD. *See* Cardiovascular disease
 - Cyclooxygenase (COX), 399
 - Cystic fibrosis, 118
- ## D
- Dandruff, microbiome, 249–250
 - Darier’s disease, gene mutations, 35–38
 - Dasatinib, 420
 - DC. *See* Dendritic cell
 - Dctn1*, 63
 - Dendritic cell (DC)
 - dermal immune function, 197
 - epidermal immune function, 195–196
 - immune response, 201–202
 - psoriasis
 - immunopathogenesis, 340–342
 - plaque-type psoriasis, 331
 - Dermal papilla (DP)
 - cell types, 221–222
 - hair follicle development and regeneration
 - anagen phase
 - functions, 218–219
 - initiation, 217–218
 - termination, 219–220
 - cell number correlation with hair size and type, 216
 - genetic manipulation in mice, 216
 - hair pigmentation role, 219
 - overview, 213–215
 - prospects for study, 222–223
 - size maintenance, 220
 - specification by placodal signals, 220–221
 - Desmoplakin (Dp)
 - functional overview, 91–92
 - transcriptional regulation, 98
 - Desmosome
 - autoimmune disease, 101–102
 - barrier function, 78–79, 99–100
 - dynamics, remodeling, and turnover, 104–106
 - gene mutations in skin disease, 38
 - morphogenesis and homeostasis of stratified tissues, 98–99
 - pathogenesis of inherited skin and heart disease, 102–104
 - pharmacological targeting, 106
 - prospects for study, 106–107
 - skin cancer dysfunction, 100–101
 - structure and organization, 91–93
 - toxin targeting, 102
 - transcriptional regulation of component expression, 93–98
 - DICER, 173
 - Dimethylbenzanthracene (DMBA), squamous cell carcinoma induction, 386–390, 399–400

Index

- DKK1, 169, 232, 360
Dlg, 65
DLL1, 9, 318
DMBA. *See* Dimethylbenzanthracene
DNA methylation. *See* Epigenetics
DNA microarray, polygenic skin disease studies, 43–44
DNA-PK, 309
DNMT1, 44, 286–287
Dorfman–Chanarin syndrome, 81
Dp. *See* Desmoplakin
DP. *See* Dermal papilla
Dsc1, transcriptional regulation, 93, 96
Dsc2
 therapeutic targeting, 106
 transcriptional regulation, 96–97
Dsc3, transcriptional regulation, 97
Dsg1
 autoimmunity, 210
 functional overview, 91–92
 striate palmoplantar keratoderma mutations, 36–38
 toxin targeting, 102
 transcriptional regulation, 93, 95
 transcriptional regulation, 95
Dsg2
 functional overview, 91–92
 skin cancer studies
Dsg3
 interfollicular stem cell expression, 9
 therapeutic targeting, 106
 transcriptional regulation, 95–96
Dsg4
 localized autosomal recessive hypotrichosus mutations, 36
 transcriptional regulation, 96
DSH, 176
Dystrophic epidermolysis bullosa. *See* Recessive dystrophic epidermolysis bullosa
- E**
- EB. *See* Epidermolysis bullosa
Ebf1, 149
EBS. *See* Epidermolysis bullosa simplex
Eccrine sweat gland. *See* Sweat gland
EDA, 46, 119–120
EGF. *See* Epidermal growth factor
EH. *See* Epidermolytic hyperkeratosis
Elovl proteins, barrier function, 80
Embryonic stem cell (ESC), pluripotency, 474–475
Endothelial cell, dermal function, 197
Eosinophil, dermal immune function, 198
EphA2, 417
Epidermal growth factor (EGF)
 gene therapy, 437
 receptor
 Notch interactions, 319–320
 ultraviolet activation, 262
Epidermal stem cell
 bone marrow, 460–461
 hair follicle. *See* Hair follicle
 histone modification effects on activation and differentiation, 290–291
 interfollicular epidermis, 9–10
 lineage tracing
 glandular stem cells, 24–26
 hair follicles, 22–24
 interfollicular epidermis
 maintenance and repair by stem cells, 18–21
 mouse versus human, 21–22
 principles, 4–5, 16–18
 re-epithelialization, 182–184
 sebaceous gland, 8–9
 sweat gland, 10
 techniques for study
 clonogenic assays, 4
 label retention, 3–4
 overview, 2–3
 skin reconstitution, 4
 lineage tracing, 4–5
Epidermolysis bullosa (EB)
 gene therapy, 432–433
 fibroblast cell therapy
 overview, 444, 456
 recessive dystrophic epidermolysis bullosa, 456–457
 revertant cell therapy, 463
Epidermolysis bullosa simplex (EBS)
 gene therapy, 435
 keratin mutations, 33, 37, 45–46
Epidermolytic hyperkeratosis (EH), keratin mutations, 33
Epidermolytic palmoplantar keratoderma (EPPK), *KRT9* mutations, 34–35, 40
Epigenetics
 chromatin remodeling
 histone modifications, 288–290
 overview, 283
 SWI/SNF, 292–293
 DNA methylation, 282, 286
 epidermal differentiation regulation
 DNA methylation, 286–287
 histone modification, 290–292
 knockout mouse studies, 284–285
 nuclear dynamics, 294
 prospects for study, 294–296
 H3K27me3 regulation, 289–290
 overview, 281–282
 polygenic skin disease studies, 44–45, 49, 287–288
EPLIN, 106
EPPK. *See* Epidermolytic palmoplantar keratoderma
ERBB-2, sweat gland carcinoma expression, 127
ESC. *See* Embryonic stem cell
Estrogen, adipocyte regulation, 152

- F**
- FALDH. *See* Fatty aldehyde dehydrogenase
FATP4, 79
- Fatty aldehyde dehydrogenase (FALDH), 40, 436
- FDH. *See* Focal dermal hypoplasia
- FGE. *See* Fibroblast growth factor
- Fibroblast
- dermal function, 197
 - epidermolysis bullosa cell therapy
 - overview, 444, 456
 - recessive dystrophic epidermolysis bullosa, 456–457
- Fibroblast growth factor (FGF)
- dermal papilla, 217, 219–220
 - FGF-9 in hair follicle neogenesis, 187–188
 - FGF-13* position effects, 48
 - hair follicle macroenvironment, 234–237
 - placode expression, 221
- Filaggrin (FLG), 41, 77, 83, 196, 363
- Finasteride, 360
- FLI*, 44
- FLG. *See* Filaggrin
- Focal dermal hypoplasia (FDH), gene mutations, 47
- FoxO, 305
- FRMD4A, interfollicular stem cell expression, 10
- Functional cloning, inherited skin disease studies, 33
- G**
- GANT58, 379
- GANT61, 379
- Gap junction, barrier function, 78
- Gata3, epidermal barrier formation role, 82
- Gene therapy
- cell therapy combination, 464
 - indications
 - epidermolysis bullosa, 432–433
 - epidermolysis bullosa simplex, 435
 - ichthyosis
 - harlequin ichthyosis, 436
 - lamellar ichthyosis, 435–436
 - junctional epidermolysis bullosa, 434–435
 - melanoma, 435
 - Netherton syndrome, 437
 - pachyonychia congenita, 435
 - recessive dystrophic epidermolysis bullosa, 433–434
 - Sjögren–Larsson syndrome, 436
 - wound healing, 435–437
 - xeroderma pigmentosum, 436
 - induced pluripotent stem cells, 480
 - overview, 427–428
 - plasmid DNA vectors
 - administration, 431–432
 - design, 430–431
 - prospects, 437
 - revertant mosaicism, 432
 - virus vectors
 - adeno-associated virus, 430
 - adenovirus, 430
 - comparison of vectors, 429
 - retrovirus, 428–429
- Generalized hypertrichosis terminalis (CGHT), 48
- Genome-wide association studies (GWAS), polygenic skin disease studies, 41–43
- GH. *See* Growth hormone
- GI-58, 81
- GLI, 7, 9, 374, 377–380
- GNAI1*, 416, 419
- GNAQ*, 416, 419
- GNAS*, 277
- Grhl3, epidermal barrier formation role, 82–83
- GRIN2A*, 417
- Griscelli syndrome, 174
- GRM3*, 417–418
- Growth hormone (GH), adipocyte regulation, 151
- GWAS. *See* Genome-wide association studies
- H**
- H19, 277
- Hailey–Hailey disease, gene mutations, 35
- Hair follicle (HF)
- advantages in regeneration studies, 228–229
 - dermal papilla in development and regeneration
 - anagen phase
 - functions, 218–219
 - initiation, 217–218
 - termination, 219–220
 - cell number correlation with hair size and type, 216
 - cell types, 221–222
 - genetic manipulation in mice, 216
 - hair pigmentation role, 219
 - overview, 213–215
 - papilla size maintenance, 220
 - prospects for study, 222–223
 - specification by placodal signals, 220–221
 - embryogenesis, 2
 - innervation, 139–141
 - macroenvironment regulation of hair cycling
 - overview, 227–229
 - prospects for study, 237–239
 - regenerative wave patterns and coordinated stem cell activation, 232–236
 - signaling
 - complexity, 236–237
 - interplay with hair follicles, 230–232
 - neogenesis, 186–188
 - Notch signaling, 314, 316
 - p53/p63 in development and cycling, 306

Index

- Hair follicle (HF) (*Continued*)
stem cells
 bulge stem cell, 5–8
 hair germ, 7
 lineage tracing, 22–24
 upper hair follicle, 8–9
Harlequin ichthyosis (HI), gene therapy, 436
HDAC1, 291–292, 305
HDAC2, 291–292, 305
HED. *See* Hypohidrotic/anhidrotic ectodermal dysplasia
Hedgehog (HH), basal cell carcinoma
 mutations, 373–374
 therapeutic targeting, 375–376, 378–380
Hedgehog. *See also* Sonic Hedgehog
Hermansky–Pudlak syndrome, 174
Hes1, 319
HF. *See* Hair follicle
HH. *See* Hedgehog
HI. *See* Harlequin ichthyosis
Hippo, cell growth role, 68–69
Histone modification. *See* Epigenetics
HLA-B13, 41
HLA-C, 334–335, 338
HMGB1, 4641, 464
Hookworm, immune response, 206–207
HOTAIR, 273, 275
HOTTIP, 275
HOXA13, 169
HOXC, 273
HOXD, 273
HPI-1, 379
HPV. *See* Human papilloma virus
Human papilloma virus (HPV), 204–205, 246
Human polyomavirus, 246
Hygiene hypothesis, 207
Hypersensitivity reactions, 208
Hypohidrotic/anhidrotic ectodermal dysplasia (HED), 119–121, 126
- I**
- Ichthyosis. *See* Harlequin ichthyosis; Lamellar ichthyosis
IFE. *See* Interfollicular epidermis
IGFBP7, 170
IL-6. *See* Interleukin-6
IL-17. *See* Interleukin-17
IL-23. *See* Interleukin-23
Immune response, skin
 aging effects, 260
 allergy, 207–208
 autoimmunity, 208–211
 bacteria, 202–204
 dermis, 197–199
 epidermis, 195–197
 fat layer, 199–200
 fungus, 205–206
 inflammation termination and wound healing initiation, 202
 initiation and evolution, 200–202
 malignancy, 211
 overview, 194–195
 parasite, 206–207
 virus, 204–205
Induced pluripotent stem cell (iPSC)
 clinical applications in dermatology
 challenges in research, 482–483
 disease modeling, 482
 gene correction therapy, 490–491
 reprogramming cells in inherited skin disease, 478–480
 revertant mosaicism, 481–482
 skin cell differentiation, 490
 tissue rejuvenation, 481
 donor cell type for reprogramming, 477–478
 generation, 475–477
 overview, 473–474
 pluripotency, 474–475
 prospects for study, 483
Inflammation
 Notch signaling in skin, 320–321, 323
 squamous cell carcinoma, 399–401
 termination and wound healing initiation, 202
Inner root sheath (IRS), formation, 214–215
Interferon, fat layer immune function, 200
Interfollicular epidermis (IFE)
 epidermal stem cells
 maintenance and repair by stem cells, 18–21
 mouse versus human, 21–22
 overview, 9–10
 Notch signaling, 314, 317–318
Interleukin-6 (IL-6), 153
Interleukin-17 (IL-17), psoriasis
 immunopathogenesis, 340–342
 therapeutic targeting, 346
Interleukin-23 (IL-23), psoriasis
 immunopathogenesis, 340–342
Intermediate filaments, gene mutations in skin disease, 38–40
Involucrin, 182
Involucrin, 390
IPEX syndrome, 199
iPSC. *See* Induced pluripotent stem cell
IRS. *See* Inner root sheath
- J**
- JEB. *See* Junctional epidermolysis bullosa
Junctional epidermolysis bullosa (JEB)
 gene therapy, 434–435
 induced pluripotent stem cell therapy, 478, 480
 LAMA5 mutations, 33–34
 mosaicism, 45

- K**
- KCNQ1OT1, 277
- Keratin
- barrier function, 77–78
 - K14
 - epidermolysis bullosa simplex gene therapy, 435
 - interfollicular stem cell expression, 9
 - K15
 - bulge stem cell expression, 7–8
 - targeting of bulge stem cells, 5–6
 - skin disease mutations
 - Darier’s disease mutations, 35
 - epidermolysis bullosa simplex, 33, 37, 45–46
 - epidermolytic hyperkeratosis, 33
 - KRT9* mutations in epidermolytic palmoplantar keratoderma, 34–35, 40
 - sweat gland
 - expression in development, 118–119
 - stem cell expression, 10
- Keratinocyte
- culture and skin grafting, 444
 - epidermal function, 195
 - gene therapy. *See* Gene therapy
 - induced pluripotent stem cell differentiation, 480
 - psoriasis
 - activation, 339–340
 - generalized pustular psoriasis, 332
 - immunopathogenesis, 340–342
 - plaque-type psoriasis, 331
- Keratinocyte growth factor (KGF), 155
- KGF. *See* Keratinocyte growth factor
- KIF13A, 172
- KIT*, 419–420
- KLF, adipogenesis, 149
- KLF4, 82, 293, 475
- L**
- LAH. *See* Localized autosomal recessive hypotrichosis
- LAMA5, junctional epidermolysis bullosa mutations, 33–34
- LAMB3, 45, 434–435, 464, 478
- Lamellar ichthyosis (LI), gene therapy, 435–436
- Langerhans cell (LHC), 196, 201, 205
- LECT1, 81
- LEKT1, 102, 107, 437
- LEOPARD syndrome, 165, 173, 177
- Leptin, 153, 155
- LFA-1, 197
- Lgl, 65–66
- LGN*, 63
- LGR-5, bulge stem cell marker, 6
- LGR-6, 8–9, 24, 183–184
- LHC. *See* Langerhans cell
- LHX2, bulge stem cell marker, 6
- LI. *See* Lamellar ichthyosis
- Lichen planopilaris. *See* Alopecia
- Lineage tracing. *See* Epidermal stem cell
- Linkage analysis, polygenic skin disease studies, 40–41
- LKB1, 65, 67, 173
- LMNA*, 154
- lncRNA. *See* Long noncoding RNA
- Localized autosomal recessive hypotrichosis (LAH), DSG4 mutations, 36
- Long noncoding RNA (lncRNA)
- overview, 271–273
 - prospects for study, 278
 - skin function
 - ANCR, 275
 - genetic syndromes with cutaneous manifestations, 276–278
 - HOTAIR, 273, 275
 - HOTTIP, 275
 - overview, 274
 - skin cancer, 275–276
 - SPRY4-IT1, 276
 - TINCR, 276
- Loose anagen syndrome. *See* Alopecia
- LRIG1, epidermal stem cell expression, 8, 10, 26
- Lrig1, 183
- M**
- Macrophage, dermal immune function, 197–198
- Malassezia*, dandruff role, 249
- Mannose binding lectin (MBL), 199
- MAPK. *See* Mitogen-activated protein kinase
- MART-1, 171–172, 210, 435
- Mast cell, dermal immune function, 198
- MBL. *See* Mannose binding lectin
- MC1R*, 411, 413–414
- MCC. *See* Merkel cell carcinoma
- McSC. *See* Melanocyte stem cell
- MCSF, interfollicular stem cell expression, 9
- Mek1, 399
- Melanocyte
- development, 164
 - epidermal function, 195–196
 - heterogeneity, 164, 169–170
 - melanin synthesis regulation
 - enzymes in synthesis, 172
 - melanosome structural proteins, 171–172
 - overview, 170–171
 - trafficking proteins, 172
 - transcription factors, 172–173
 - melanoma, 177
 - overview, 163–164
 - pigmentary disorders
 - hyperpigmentation disorders
 - acquired, 173–174
 - congenital, 173

Index

- Melanocyte (*Continued*)
hypopigmentation disorders
 acquired, 175–176
 congenital, 174–175
mixed disorders, 176
table, 165–169
vitiligo, 176–177
prospects for study, 177–178
senescence, 170
stem cells, 170
- Melanocyte stem cell (McSC), hair follicle
 neogenesis, 188
- Melanoma. *See also* Skin cancer
acral melanoma gene mutations, 419–420
aggressive disease genomic expression patterns,
 420–421
BRAF mutations, 414–416, 418
clinical phenotypes, 409–410
epidemiology, 410–411
gene therapy, 435
hereditary loci, 411–413
MC1R variants, 411, 413–414
melanomagenesis, 411
mucosal melanoma gene mutations, 419–420
NRAS mutations, 416–417
PI3K/AKT/mTOR mutations, 418
prospects for study, 421
RAC1 mutations, 417
receptor tyrosine kinase mutations, 417–418
regulatory protein mutations, 418–419
susceptibility genes, 177
ultraviolet mutagenesis, 414–415
uveal melanoma gene mutations, 419
- Menkes disease, 174
- Merkel cell
 epidermal function, 195
 neurite complexes in touch domes, 135–139
- Merkel cell carcinoma (MCC)
 microbiome, 250
 overview, 138–139
- Mesenchymal stem cell (MSC), dystrophic epidermolysis
 bullosa cell therapy, 458–459
- Mesenchymal-to-epithelial transition (MET), 477–478
MET. *See* Mesenchymal-to-epithelial transition
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 202
- Microbiome, skin
 bacteria, 244–246
 diagnostic and therapeutic potential, 250–251
 diseases
 acne vulgaris, 249
 atopic dermatitis, 247–249
 dandruff, 249–250
 Merkel cell carcinoma, 250
 psoriasis, 249
 fungi, 246
 prospects for study, 251–252
 techniques for study, 242–244
 viruses, 246–247
- Microneedle, plasmid DNA gene therapy
 administration, 431–432
- MicroRNA (miRNA)
 p63 effects, 305
 skin disease studies, 44
- Minoxidil, 360
- miRNA. *See* MicroRNA
- MITF, 170, 172–173, 176, 413–414
- Mitogen-activated protein kinase (MAPK), ultraviolet
 activation, 263
- MLL1 complex, 275
- Mosaicism, skin disease studies, 45–47
- MRM, 309
- MRP6*, 38, 40
- MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
- MSC. *See* Mesenchymal stem cell
- mTOR, 418
- N**
- Natural killer (NK) cell, dermal immune function, 198
- NEMO, 47, 176
- Netherton syndrome, gene therapy, 437
- Neutrophil, dermal immune function, 198
- NF- κ B. *See* Nuclear factor- κ B
- NFATC1, bulge stem cell marker, 6
- Nickel allergy, 208
- NIF, 207
- NK cell. *See* Natural killer cell
- NLRs. *See* NOD-like receptors
- NOD-like receptors (NLRs), 200
- Noonan syndrome, 173
- Notch
 cross talk, 318–320
 functional analysis of cutaneous signaling, 317–318
 hair follicles, 314, 316
 inflammation regulation in skin, 320–321, 323
 interfollicular epidermis, 314, 317–318
 prospects for study, 324–325
 receptors, 315–316
 signaling overview, 313–314
 skin cancer tumor suppressor, 321–323
 squamous cell carcinoma signaling, 397–399
- NRAS*, melanoma mutations, 416–417
- NUAK2, 170
- Nuclear factor- κ B (NF- κ B), sweat gland development
 signaling, 119–120
- Numa1*, 63
- NURE, 293
- O**
- Oct-4, 475
- Oculocutaneous albinism, 174

- P**
- p16, 418
 - p21, 318–319, 322, 397
 - p53, 126–127, 291
 - family and isoforms, 302–303
 - hair follicle development and cycling role, 306
 - overview, 301–302
 - prospects for study, 309–310
 - skin cancer mutations, 308
 - skin response to chemotherapy, 309
 - squamous cell carcinoma
 - knockout mice, 396–397
 - mutations, 386
 - p63
 - epidermal development role, 303–305
 - hair follicle development and cycling role, 306
 - isoforms, 302–303
 - Notch interactions, 319
 - skin cancer role, 308
 - wound healing role, 306–308
 - p73
 - isoforms, 302–303
 - skin cancer role, 308–309
 - Pachyonychia congenita, gene therapy, 435
 - Par proteins. *See* Cell polarity
 - PARP1, 418
 - PDGF. *See* Platelet-derived growth factor
 - PEKAR1A, 173
 - Perp, 101
 - Peutz–Jegher syndrome (PJS), LKB1
 - mutations, 65, 165
 - Pg. *See* Plakoglobin
 - Phototherapy, psoriasis, 342
 - PI3K, 378, 380, 392, 418
 - PJS. *See* Peutz–Jegher syndrome
 - PKC. *See* Protein kinase C
 - Pkp. *See* Plakophilin
 - PKP1, 38
 - Plakoglobin (Pg)
 - functional overview, 91–92
 - transcriptional regulation, 97–98
 - Plakophilin (Pkp)
 - functional overview, 91–92
 - transcriptional regulation, 98
 - Platelet-derived growth factor (PDGF)
 - adipogenesis, 150
 - gene therapy, 437
 - hair regeneration, 150
 - PLC- ϵ , 392–393
 - PLET1, 8
 - PMEL17, 171–172
 - POEMS syndrome, 174
 - Polarity. *See* Cell polarity
 - PORCN, 47
 - Position effects, skin disease studies, 47–48
 - PPAR γ
 - adipogenesis, 149
 - lichen planopilaris pathogenesis, 368
 - mutations, 154–155
 - PRINS, 274
 - Propionibacterium acnes*, 249, 251
 - Protein A, 203
 - Protein kinase C (PKC)
 - basal cell carcinoma therapeutic targeting, 379–380
 - desmosome regulation, 94, 105
 - polarity signaling by aPKC, 58, 61–67
 - Psoriasis
 - biomarker discovery, 347–349
 - classification and histology
 - erythrodermic psoriasis, 332
 - generalized pustular psoriasis, 332
 - guttate psoriasis, 332
 - plaque-type psoriasis, 330–331
 - comorbidity, 333–334
 - environmental triggers, 339
 - epidemiology, 330
 - etiopathogenesis, 334
 - genetics
 - genome-wide association studies, 335, 338–339
 - overview, 334–335
 - PSORS1, 335
 - susceptibility genes, 335–337
 - immunopathogenesis
 - established disease, 341–342
 - initiation, 340–341
 - overview, 339–340
 - microbiome, 249
 - prospects for study, 349
 - psoriatic arthritis, 332–333
 - treatment, 342–347
 - PSORS1, 335
 - PTCH1, 374–376
 - PTEN, 305, 397, 418
- R**
- RA. *See* Retinoic acid
 - Rac, 65, 393
 - RAC1, melanoma mutations, 417
 - Raf-1, 392, 395
 - RalGDS, 395
 - RAS, squamous cell carcinoma
 - effectors, 392–396
 - mutations, 386–388, 391
 - RBP-J, 317, 320, 323
 - RDEB. *See* Recessive dystrophic epidermolysis bullosa
 - Recessive dystrophic epidermolysis bullosa (RDEB)
 - cell therapy
 - bone marrow stem cells, 458–460
 - bone marrow transplant, 459–460
 - fibroblasts, 456–457
 - induced pluripotent stem cells, 478–480

Index

- Recessive dystrophic epidermolysis bullosa (RDEB) (*Continued*)
 mesenchymal stem cells, 458–459
 revertant cell therapy, 463
 COL7A1 mutations, 34, 37
 gene therapy, 433–434
- Regeneration
 adipocyte in hair regeneration, 149–150
 aging effects on skin regenerative capacity, 259
 cell polarity role, 64–65
 hair follicle neogenesis, 186–188
 prospects for study, 188–190
 sweat glands, 124–126
- Retinoic acid (RA), Notch interactions, 319
- Retrovirus, gene therapy, 428–429
- Revertant mosaicism
 cell therapy combination, 465
 gene therapy, 432, 462–463
 induced pluripotent stem cells, 481–482
- RhoA, 101–102, 105
- RILP, 172
- RNA sequencing, polygenic skin disease studies, 43–44
- S**
- S6 kinase, 380
- Satb1, 294
- SCC. *See* Squamous cell carcinoma
- SCD. *See* Symmetric cell division
- Schwann cell, type II terminal cells, 140
- SCIN, 203
- SCNT. *See* Somatic cell nuclear transfer
- Scribble, 65
- Sebaceous gland, epidermal stem cells
 lineage tracing, 25–26
 markers, 8–9
- Sept4*/ARTS, 184
- SHH. *See* Sonic Hedgehog
- SHOC2, 99, 102, 365
- SHP-1*, 44
- Sjögren–Larsson syndrome (SLS), gene therapy, 436
- SKH-1*, 386
- Skin cancer
 cell polarity role, 65–66
 DNA methylation alterations, 287–288
 long noncoding RNAs, 275–276
 Notch as tumor suppressor, 321–323
 p53 mutations, 308
 p63 role, 308
 p73 role, 308–309
- Skin cancer. *See also specific cancers*
 desmosome dysfunction, 100–101
 sweat glands, 126–127
- SLC45A2, 172
- SLS. *See* Sjögren–Larsson syndrome
- Slug, 94
- SMO, 374–378
- Somatic cell nuclear transfer (SCNT), 474
- Sonic Hedgehog (SHH)
 bulge stem cell marker, 6
 sweat gland development signaling, 121
- Sorafenib, 420
- Sox-2, 475
- SOX-9, bulge stem cell marker, 6
- SPINK5*, 81, 437
- SPPK. *See* Striate palmoplantar keratoderma
- SPRY4-IT1, 276
- Squamous cell carcinoma (SCC). *See also*
 Skin cancer
 gene mutations, 380–381
 inflammation, 399–401
 mouse models
 chemical induction, 386–388
 initiation target cell identification, 388–390
 knockout mice, 396–397
 Notch signaling, 397–399
 Ras effectors, 392–396
 transgenic mice, 390–382
 ultraviolet radiation carcinogenesis, 386
 prospects for study, 401
- ST14*, 81
- Staphylococcal scalded skin syndrome, 102
- Staphylococcus aureus*
 atopic dermatitis role, 247
 immune response, 202–204
- STAT3, 101
- Streptococcus*, psoriasis role, 249
- Striate palmoplantar keratoderma (SPPK),
 DSG1 mutations, 36–38
- SUFU, 374, 378
- Sweat gland
 development
 apocrine sweat glands, 118
 eccrine sweat glands, 116–119
 signaling, 119–121
 disorders, 126–127
 epidermal stem cells
 lineage tracing, 25–26, 119
 markers, 10
 homeostasis, 121–123
 regeneration, 124–126
 types and functions, 115–116
 wound repair
 epidermal injury, 123
 glandular injury, 123–124
- SWI/SNF, 292–293
- Symmetric cell division (SCD), 62–63, 65
- T**
- Taf10, epidermal barrier formation role, 82
- Tamoxifen, epidermal stem cell lineage tracing, 4

- TAT, 477
- TBX1, bulge stem cell marker, 6
- T cell
 - autoimmunity, 209–211
 - bacteria immune response, 203–204
 - dermal immune function, 198–199
 - fungus immune response, 205–206
 - helper cells, 201, 205–206
 - memory T cell epidermal immune function, 196–197
 - parasite immune response, 206–207
 - psoriasis
 - immunopathogenesis, 340–342
 - plaque-type psoriasis, 331
 - therapeutic targeting, 343
 - virus immune response, 204–205
- TCF-3, bulge stem cell marker, 6
- Telogen effluvium. *See* Alopecia
- Telomerase reverse transcriptase (TERT), 419, 481
- TERT. *See* Telomerase reverse transcriptase
- TEWL. *See* Transepidermal water loss
- TGF- β . *See* Transforming growth factor- β
- TGM1, 39–40, 76–77
- Thyroid hormone, adipocyte regulation, 152
- Tiam1, 393
- Tight junction (TJ)
 - barrier function, 78
 - cell polarity, 60–61
- TINCR, 276
- TJ. *See* Tight junction
- TLRs. *See* Toll-like receptors
- TNF. *See* Tumor necrosis factor
- Tofacitinib, psoriasis management, 346
- Toll-like receptors (TLRs), 200, 205
- Touch receptors
 - hair follicle innervation, 139–141
 - Merkel cell–neurite complexes in touch domes, 135–139
 - overview, 133–134
 - prospects for study, 141
 - sensory neurons, 134
- TPA, squamous cell carcinoma induction, 386–390, 399–400
- Traction alopecia. *See* Alopecia
- Transepidermal water loss (TEWL), 74, 78–79, 82
- Transforming growth factor- β (TGF- β)
 - hair follicle macroenvironment, 236–237
 - ultraviolet effects, 264
 - wound healing, 186, 202
- Trichotillomania. *See* Alopecia
- TRPS1, 48
- TSLP, 323, 400–401
- TSST-1, 204
- Tumor necrosis factor (TNF)
 - knockout mice, 399
 - psoriasis
 - immunopathogenesis, 340, 342
 - therapeutic targeting, 343, 347
- Twin studies, polygenic skin disease studies, 40–41
- TYRP1, 172
- U**
- ULPB3, 43
- Ultraviolet radiation (UV)
 - collagen fibril degradation, 261–264
 - dermal structure effects, 262–264
 - DNA methylation effects, 288
 - melanoma mutagenesis, 414–415
 - photoaging, 257
 - pigmentary system effects, 259–260
 - psoriasis phototherapy, 342
 - squamous cell carcinogenesis, 386
- Umbilical cord blood, cell therapy, 461–462
- Uniparental disomy (UPD), skin disease studies, 47
- UPD. *See* Uniparental disomy
- UV. *See* Ultraviolet radiation
- V**
- Vascular endothelial growth factor (VEGF), gene therapy, 436–437
- VEGF. *See* Vascular endothelial growth factor
- Vinculin, 106
- Vismodegib, basal cell carcinoma management, 375–376
- Vitiligo, 176–177, 209–210
- W**
- Warts, 203
- WIF-1, 174
- Wilson disease, 174
- Wnt
 - hair follicle
 - macroenvironment, 232, 234–237
 - neogenesis, 187
 - sweat gland development signaling, 120–121
- Wound healing
 - adipocyte, 147–148, 150
 - dystrophic epidermolysis bullosa fibroblast cell therapy, 457
 - gene therapy, 435–437
 - inflammation termination and wound healing initiation, 202
 - overview, 181–182
 - p63 role, 306–308
 - prospects for study, 188–190

Index

Wound healing (*Continued*)

re-epithelialization and epithelial stem cells,
182–184

scarless wound healing in mammals,
184–186

sweat glands

epidermal injury, 123

glandular injury, 123–124

X

Xeroderma pigmentosum (XP), gene therapy, 436

XP. *See* Xeroderma pigmentosum

Z

Zeb, 94

ZO-1, 100